Personalized Therapy for Multiple Myeloma

Provides concise practical guidance on the management of multiple myeloma

Summarizes the latest clinical trial and research data

Covers the treatment of different phases and forms of disease, including high-risk myeloma

Provides concise practical guidance on the management of multiple myeloma Summarizes the latest clinical trial and research data Covers the treatment of different phases and forms of disease, including high-risk myeloma Includes supplementary material: sn.pub/extras

Autorentext

Saad Zafar Usmani is Director of the Plasma Cell Disorder Program and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA. He is an internationally recognized clinical and translational researcher who focuses on plasma cell disorders in general, and high-risk multiple myeloma in particular. He is a specialist in Hematology, Medical Oncology, and Bone Marrow Transplantation. He also holds an academic appointment as Clinical Professor of Medicine at the UNC-Chapel Hill School of Medicine. Dr. Usmani received his medical education at Allama Iqbal Medical College, Lahore, Pakistan. He is on the editorial review board of numerous medical journals and has authored or co-authored more than 150 peer-reviewed manuscripts and abstracts.

Ajay Kumar Nooka is Assistant Professor of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. Dr.Nooka is board certified in Internal Medicine and specializes in Hematology and Medical Oncology. Dr. Nooka's research interests include cancer epidemiology in the fields of multiple myeloma and bone marrow transplantation. His research focuses on the molecular epidemiology of myeloma. Clinically his interests include evaluating newer combinations of novel agents aimed at increasing the efficacy of myeloma therapies.

Inhalt

Risk stratification in newly diagnosed smoldering multiple myeloma.- Risk stratification in newly diagnosed transplant eligible multiple myeloma.- Risk stratification in newly diagnosed transplant ineligible multiple myeloma.- Treatment of translocation 4;14 and deletion 17 p MM.- Treatment of patients in first/second relapse.- Treatment of patients in third relapse and beyond including double refractory disease.- Treatment of primary and secondary plasma cell leukemia.- Practical considerations for bone health in multiple myeloma.- Personalizing MM treatment: gaps in knowledge that we need to overcome.